Tetanus Prophylaxis Single Domain Antibody Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tetanus, such as passive immunization with polyclonal antitoxins, face challenges including high costs, low solubility, stability issues, and reliance on animal-derived products, while existing single-domain antibodies (SDAs) against tetanus neurotoxin (TeNT) have suboptimal affinity, limiting their effectiveness in neutralizing the toxin.
Innovation Solution
Development of novel SDAs with significantly improved affinity for TeNT, achieving dissociation constants (KD) below 1 nM, allowing for high-affinity binding and toxin neutralization, and their use in combination with other SDAs targeting serum proteins to enhance stability and half-life, forming polypeptide constructs that can be easily produced and administered.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If passive immunization with polyclonal antitoxins is used, then tetanus treatment is provided, but high costs and low solubility occur
Solution Approach 1:
The patent extracts and isolates specific functional domains from the complex polyclonal antitoxin system. It identifies and produces monoclonal antibodies with specific affinity for tetanus neurotoxin, separating the effective neutralizing function from the costly and insoluble polyclonal mixture, thereby achieving effective treatment at lower cost with improved solubility
Solution Approach 2:
The patent changes the molecular parameters of the antibody system by switching from polyclonal to monoclonal antibodies. This parameter change results in improved solubility, reduced production cost, and maintained therapeutic effectiveness through the use of recombinant monoclonal antibodies with controlled molecular properties
2Ease of manufacture
If existing single-domain antibodies (SDAs) against TeNT are used, then production cost is reduced, but affinity is suboptimal limiting effectiveness
Solution Approach 1:
The patent optimizes the affinity parameter of single-domain antibodies by identifying and producing monoclonal SDAs with enhanced binding strength to tetanus neurotoxin. Through parameter optimization in the variable regions, it achieves high affinity (KD < 1 nM) while maintaining the cost advantages of SDA production
Solution Approach 2:
The patent creates refined copies of the SDA structure through monoclonal antibody technology. By producing multiple identical monoclonal antibody molecules with optimized binding sites, it achieves superior affinity compared to the original SDA approach, effectively neutralizing the toxin with higher reliability
3Reliability
If polyclonal antitoxins are used, then immediate protection is provided, but stability issues occur
Solution Approach 1:
The patent extracts the stable, protective function from the unstable polyclonal antitoxin composition. By isolating and producing monoclonal antibodies with consistent molecular structure, it maintains the immediate protection benefit while achieving superior compositional stability through homogeneous molecular composition
Solution Approach 2:
The patent introduces homogeneity by producing monoclonal antibodies with identical molecular structures. This homogeneous composition provides stable antitoxin that maintains consistent protective activity over time, eliminating the stability issues inherent in heterogeneous polyclonal preparations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel SDAs demonstrate enhanced affinity and in vivo tetanus toxin neutralizing activity, effectively suppressing tetanus symptoms by shifting the balance of TeNT molecules towards bound forms, and the polypeptide constructs exhibit extended half-life and improved clinical utility.
Implementation Method 1
Development of novel SDAs with significantly improved affinity for TeNT, achieving dissociation constants (KD) below 1 nM, allowing for high-affinity binding and toxin neutralization
Implementation Method 2
The novel SDAs demonstrate enhanced affinity and in vivo tetanus toxin neutralizing activity, effectively suppressing tetanus symptoms by shifting the balance of TeNT molecules towards bound forms
Data Source
AI summary
The present invention relates to single domain antibodies (SDAs) that are capable of binding to tetanus neurotoxin. The invention further relates to polypeptide constructs comprising such an SDA as well as an SDA that is capable of binding to a serum protein, preferably to serum albumin or immunoglobulin. The invention also relates to nucleic acids encoding such SDAs or polypeptide constructs, to pharmaceutical compositions comprising such SDAs or polypeptide constructs, the medical use thereof and to their use in the treatment of tetanus.